I N T R O D U C T I O N
The immune system is molded by histories of infections, and prior exposure to one pathogen may influence resistance to a second unrelated pathogen. Congenitally infected LCMV carrier mice lack T cell responses to LCMV but resist infections by a wide variety of viruses, perhaps due to chronic production of low levels of type 1 IFN (7) . Hosts acutely infected with many viruses can generate very high levels of type 1 IFN that provides strong resistance to superinfection (54) . Mice latently infected with murine cytomegalovirus (MCMV) or mouse herpes virus chronically reactivate these viruses, whose antigens stimulate IFN production by memory T cells; this provides resistance to Listeria monocytogenesis and Yersinia pestis, which grow poorly in IFN -activated macrophages (4).
One does not, however, need ongoing infections like the above to provide resistance to newly encountered pathogens. In a phenomenon known as heterologous immunity, the immune memory lymphocyte repertoire created in response to one pathogen may influence the immune response to another unrelated pathogen, particularly if antigens from the second pathogen can cross-reactively stimulate the memory pool (55) . The degenerative nature of T cell recognition, where an antigenic peptide is presented in the context of an MHC molecule (45) , and where the T cell receptor undergoes conformational shifts to recognize a peptide/MHC complex (5) , enhances the probability of cross-reactivity between unrelated pathogens. Indeed, cross-reactive CD8 T cells have been reported between the antigens of influenza virus and Epstein-Barr virus (EBV) (11) , hepatitis C virus (HCV) (52) , and HIV (2) , between HIV and M. tuberculosis activated by cytokines such as IL-12 and IL-18 independently of TCR signaling (15, 35) , and the significance of that mechanism in heterologous immunity needs to be determined. (33) . Several early reports indicated that a recent exposure of mice to BCG or to M. tuberculosis rendered them more resistant to infection to a variety of bacteria and to ectromelia virus (16, 40, 44) , the mouse form of smallpox, and to VV (3, 56) , which is used for vaccination of humans against smallpox. An unspecified IFN was suggested to be involved in the protection against ectromelia (40, 44) . Given the importance of these vaccines and pathogens, we have examined the mechanism of this protection, using modern immunological approaches. We show here evidence for a CD4 T cell-mediated heterologous immunity between a mycobacterium (BCG) and a virus, VV. Pathogens. VV, strain WR, was propagated in NCTC 929 cells, and purified over sucrose gradients (42) . LCMV, Armstrong strain clone 13, was propagated in BHK21
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baby hamster kidney cells, and MCMV, Smith strain, was propagated in vivo in salivary glands of BALB/c mice (42) . VV and LCMV PFU were determined by plaque assay of 10% tissue homogenates from individual mice titrated on vero cell monolayers. Titers are expressed as geometric mean titers, that is the arithmetic average of the log 10 PFU per whole spleen, liver, or both abdominal fat pads plus or minus the SD. Live attenuated M.
bovis BCG, Pasteur strain, was propagated in 7H9 broth supplemented with 10% oleic acid-albumin-dextrose-catalase (DIFCO, Becton Dickinson, Sparks, MD), 0.2% glycerol, and 0.05% Tween 80. BCG stocks for immunization were prepared from mid-log phase cultures that were washed with PBS containing 0.05% Tween 80. BCG CFU were determined by plating 10-fold dilutions on Middlebrook 7H11 agar (DIFCO). Vesicular stomatitis virus (VSV), strain Indiana, was used as a challenge virus in IFN assays (53). Synthetic peptides. Several previously defined CD8 T cell epitopes encoded by VV were used in this study (12, 30 Intracellular IFN staining. Cytokine-producing T cells were detected using the Cytofix/Cytoperm Plus Kit with GolgiPlug (BD Biosciences, Mountain View, CA), as previously described (34, 50) . Two x 10 6 mouse leukocytes from spleen, PEC, or fat pads were incubated in 96-well microtiter plates for 5 h at 37°C with 1 µM synthetic peptides or 0.1 µg/ml anti-CD3 antibody, 10 U/ml human rIL-2 (BD Biosciences) and 0.2 µl of GolgiPlug. Cells were then washed in FACS buffer (HBBS, 2% FCS, and 0.1% NaN 3 ), To determine whether this extremely small number of residual bacteria was activating the immune system, BCG-immune and sham-immune mice, all treated with antibiotics, were examined for indicators of immune system activation. Although there seemed to be some variability in BCG-immune spleen size, there were no statistically significant differences in leukocyte numbers between BCG-and sham-immunized mice when tested at 8, 10 (Table 1) (Table 2A) or LCMV (Table 2B ) and tested for viral titers in different organs at 1-3 days post-infection. Table 2 shows that BCG-immune B6 mice had normal susceptibility to LCMV but had dramatic 10-100-fold reductions in titers to VV. Mycobacteria-induced resistance to VV has been reported before, but those studies examined VV infection during ongoing immune responses early after immunization and most likely before the mycobacteria were cleared (3, 56) . Under those conditions there would be high levels of macrophage activation and cytokine production at the time of challenge. In contrast, we used experimental conditions designed to examine heterologous immunity in a resting immune state by using antibiotic-treated mice. The resistance to VV infection was long lasting, as mice were still protected against VV 28 weeks after the initial BCG immunization ( Table 2 ). The immunity manifested itself quickly, as greater than ten-fold reductions in VV titers were seen as early as day 1 after VV challenge. Similar studies with VV were done in BCG-immune B10 mice and BCG-immune MHC-congenic B10.D2 (H2 d ) mice. B10 mice are closely related to B6 mice and have the same H2 b haplotype. BCG-immune B10 mice were as resistant to VV as their B6 counterparts. The protective effect of BCG immunization to VV infection also occurred in B10.D2 mice but seemed less pronounced than that in B10 mice (Table 2A) .
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This was not further addressed, but it does suggest that this heterologous immunity can occur with different MHC. (Table 1A and Fig. 1A ), remarkable differences were seen at day 6 after infection. Spleen sizes became substantially larger in the VV-infected BCGimmune mice (Fig.1A) , reflecting larger numbers of T cells in both spleens and peritoneal cavities, where the inflammatory infiltrate was quite extensive. Expansions in the CD8 T cell populations were most profound, as shown in the representative experiment in Figure 1B ,C. Averages of CD8 numbers from three experiments (n=8)
were the following: BCG spleen=6.7 2.5 x 10 7 vs. sham spleen=3.2 1.4 x 10 7 , p = Table 2 shows that substantial differences in viral titers in spleen, visceral fat pads (lining the peritoneal cavity), and liver were detected as early as 1 or 2 days post-infection of BCG-immunized mice challenged with VV. This timing could be consistent with an early innate immune response. We thus tested the peritoneal fluid for type 1 IFNs in a bioassay and found none (titer < 1.2) prior to VV challenge (n=7) or at 6 (n=2) or 24 (n=6) hrs after i.p. infection. Sera from BCG-immune mice were tested in neutralization plaque assays against VV, and no detectable neutralizing antibody was found (titer < 1:3) (n=4).
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Heterologous immunity between LCMV and VV has been shown to be mediated by memory CD8 and CD4 T cells appearing early, with innate-like kinetics (42) . In that system, when CFSE-labeled splenocytes from LCMV-immune mice were adoptively transferred into naïve recipient mice challenged with VV, there was a dramatic increase in the number of CFSE lo donor CD8 T cells and a much less dramatic response of CD4 T cells, in comparison to naïve donor cells (20) . Generally, when CD8 T cells see antigen they undergo many rounds of clonal expansion and greatly increase in frequency (18, 27, 49) . Expansion of CD4 T cells under similar conditions is usually much more limited (14) . Nevertheless, we analyzed how well BCG-immune CD4 and CD8 T cells would proliferate after transfer into naïve mice that were subsequently challenged with VV. Three x 10 7 CFSE-labeled BCG-immune or sham-immune splenocytes (Ly5.2)
were transferred intravenously into Ly5.1 congenic B6 mice, which were inoculated with VV 4 hr later, and at day 5 or 6 post-infection the CSFE loss and total numbers of CD4 and CD8 cells were monitored (very little CFSE loss was seen at day 4 post-infection).
There was some loss of CFSE, indicative of division, in the CD8 populations, but in 5 experiments (n= a total of 14 mice per group) there were no significant differences in We therefore depleted BCG-or sham-immune mice with anti-CD4 (Table   3A ,B,C) or anti-CD8 antibodies (Table 3C ) and challenged them with VV. Depletion of CD8 T cells (and likely other CD8 + cells) had no effect on the differential protective immunity in this and in another experiment. However, depletion of CD4 T cells eliminated the differential in titers between the BCG-immune and sham-immune hosts.
Anti-CD4 treatment had no effect on the day 2 VV titers in sham-immune mice, antigenic phenotype, without additional stimulation in vitro. Figure 3 shows that very little IFN was made by CD4 or CD8 T cells isolated from spleen, peritoneum, and fat pads from unchallenged sham-or BCG-immune mice. This is further evidence that the immune system is at rest prior to VV challenge. Very little IFN was made in the spleens of VV-infected mice (Fig. 3) , perhaps because that was not the site of viral challenge and because the viral antigen load therein was low (Table 2) Table 3D , where there were no statistically significant differences between CsA-treated BCG-immune or shamimmune mice challenged with VV, and in another experiment at day 3 post-infection.
15
A C C E P T E D
CsA also prevented both the CD4 and CD8 T cells from synthesizing IFN (Fig. 3) .
These results are consistent with the concept that a TCR-dependent event regulated both cytokine production and protective immunity and that the protection was mediated by 
BCG-induced memory T cell populations respond to VV differently than do LCMVinduced memory T cell populations. The selective proliferation and probable TCR dependence of the CD4 T cells is consistent with the concept of CD4 T cell-mediated
cross-reactivity in this system, but some evidence indicates that memory T cell populations can be readily activated by cytokines, independent of TCR signaling (15, 35) .
We questioned, therefore, whether other memory T cell populations would respond to production by CD8 T cells on VV challenge (Fig. 3 ), but the opposite was true in LCMVinduced immune cell populations, where it was the CD8 T cells which preferentially synthesized the IFN in vivo after VV challenge, with much less production by the CD4
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T cells (Fig. 4) . This indicates that VV-induced cytokine production is not a function of just any heterologous memory T cell population and is more consistent with the concept of an antigen-specific response. Table 2 ). when immune responses to the mycobacteria were likely ongoing (3, 16, 40, 44, 56) . In this present report, mice were treated with antibiotics to clear residual mycobacteria to minimum levels, the immune system appeared at rest (Table 1 ; Fig. 3) , and resistance to VV challenge was still observed even more than 6 months after BCG immunization (Table 2 ). This indicates that this is true heterologous immunity and not just a resistance to infection caused by an activated innate immune system. The second novel observation is that the heterologous immunity was mediated primarily by CD4 T cells, which were shown to be activated in vivo to make IFN . The mechanism of heterologous immunity is not clarified in most systems, but a CD8 T cell mechanism has been described or suggested for heterologous immunity between influenza and HCV (48) , between influenza and EBV (11) , between different strains of dengue virus (28), and between LCMV and Pichinde virus (6, 42) . Cross-reactive CD8 T cells have been directly shown to mediate heterologous immunity between LCMV and VV in mice (6), though adoptive transfer studies of LCMV-immune splenocytes into naïve mice have also shown that CD4 T cells were necessary, along with the CD8 T cells, to mediate protective immunity against VV (42) . This is the first study demonstrating an exclusive role for CD4 cells in protective heterologous immunity, apparently independent of antibody or CD8 T cells.
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While successful with our immune depletion studies shown in Table 3 , we were unable to use adoptive transfer techniques in this system to show a protective role for memory CD4 T cells (data not shown); this is not surprising, considering the relatively poor ability of CD4 T cells to proliferate after transfer, as shown in Fig. 2 . The importance in developing an understanding of this process is attested to by epidemiological studies that have shown that vaccination with BCG, as well as other vaccines, such as measles, can sometimes provide unexpected health benefits, including greater resistance to unrelated pathogens and overall lower mortality in vaccinated third world populations (1, 22, 38, 39) . Alternatively, there is considerable debate over whether too many inactivated vaccines may alter or inhibit proper development of the immune system in industrialized nations. This hygiene hypothesis argues that living in too clean an environment with exposure to inactivated vaccines rather than normal infections may promote allergic or autoimmune responses (37) . Of interest is that the incidence of atopy in human populations is reported to be reduced by vaccination with BCG, which is an attenuated live replicating vaccine rather than an inactivated pathogen (43) .
Heterologous immunity has been implicated in increased resistance as well as enhancement of infections, with altered immunopathology in either case (9, 42, 48, 55) .
Some viruses, such as EBV, cause greater symptomatology in young adults than in children, and the characteristic pathology of EBV-associated monononucleosis has recently been linked to the activation of influenza virus-specific CD8 T cells in some patients (48) . It is noteworthy that the VV-challenged BCG-immune mice in this study It is clear from our studies that this heterologous immunity was not a consequence of an already ongoing immune response at the time of initial infection and that it was dependent on the effector function of memory-phenotype CD4 T cells (Tables 1 and 3 ).
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The question is whether this resistance was due to some cytokine-mediated non-specific activation of memory cells or due to cross-reactive memory cells activated through their TCR, and arguments can be made for both sides of this issue. Some have argued that memory cells are "twitchy" and can be activated by cytokines such as IL-12 and IL-18 independently of TCR signaling (15, 35) . The high frequency of IFN -synthesizing CD4 T cells infiltrating infected tissues as early as two days after VV challenge may be consistent with that concept. Our failure thus far to define cross-reactive epitopes or to show convincing changes in epitope-specific T cell hierarchies would also be consistent with a nonspecific process (Fig. 5 & 6) . Indeed, our demonstration that the heterologous immunity occurred in congenic mice bearing different MHC molecules is also consistent with the "nonspecific" hypothesis, as this would require additional cross-reactive epitopes to be presented by disparate class II MHC molecules.
Nevertheless, demonstration of cross-reactivity can be quite difficult, and an argument can be made in support of cross-reactivity in this model. It is becoming apparent that there may be hundreds of class II epitopes encoded by these pathogens. An increasing number of VV epitopes are now being defined (12, 29, 30, 47) , and, while less is known about the epitope spectrum for BCG and M. tuberculosis, it is likely to be quite large, considering that these organisms encode about 4000 proteins, or about 20 times the number encoded by VV (8) . Thus, the probability of their being cross-reactive CD4 epitopes between BCG and VV is high, but the probability of us detecting cross-reactivity within the small subset of potential peptides tested was low. In addition, the programmed proliferative expansion of CD4 T cells is substantially less than that of CD8 T cells and requires exposure to antigen to continue (14, 23) . VV is rapidly cleared by the CD4 T cells in BCG-immune mice (Table 2) The arguments that this heterologous immunity may be due to cross-reactivity are several. First, the protective immunity to VV was specific in that there was no protection against LCMV (Table 2 ). In addition, LCMV, unlike VV (Fig. 2) , did not induce IFN from BCG-immune T cell populations in vivo (data not shown). In two experiments (not shown) we could find no BCG-induced protective immunity against a third virus, MCMV; however, MCMV infection did induce elevated levels of IFN in BCG-immune memory CD4 cell populations, though not as high as VV did. MCMV, unlike LCMV, which encodes only four proteins, is a large complex pathogen likely to encode some epitopes cross-reactive with BCG, and is being separately studied. Second, the theory that memory cells are getting activated only by cytokines (15, 35) is challenged by experiments where we compared BCG-immune to LCMV-immune mice, both challenged with VV (Figs. 3 & 4) . Although both BCG and LCMV infections elicit CD4 and CD8 memory cell populations, VV selectively induced IFN from the BCG-immune CD4 populations, whereas it selectively induced IFN from the LCMV-immune CD8
populations. This argues for a qualitative difference in these immune T cell populations generated in response to two different pathogens, and that difference could be accounted for by differences in their TCR. Finally, TCR signaling is blocked by CsA (36) , and this drug blocked the CD4 T cell IFN production and the protective immunity to VV in the BCG-immune mice ( Fig. 3; Table 3 ). We acknowledge that CsA can at times act in a TCR-independent manner, but collectively, these experiments support a cross-reactive, TCR-dependent mechanism. 
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ABBREVIATIONS:
BCG-Bacille Calmette-Guerin, BFA-brefeldin A; CsA-cyclosporine A; EBV-EpsteinBarr virus; HCV-hepatitis C virus; LCMV-lymphocytic choriomeningitis virus; MCMV -murine cytomegalovirus; VV-vaccinia virus. a Spleen and PEC leukocytes were harvested from three B6 mice 10 weeks after BCG-or sham-immunization. Leukocyte counts reflect total counts using a hemocytometer. Cells were stained with lymphocyte activation markers and analyzed by flow cytometry. Analysis of lymphocyte markers is based on a lymphocyte gate. 
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